Clinical Trial

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Study acronym: Tarian-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.
Protocol Amendment History 1 change
notable Trial sites expanded: 24 -> 40 locations 2026-04-25
Trial Details
NCT Number NCT07300969
Lead Sponsor Draig Therapeutics Ltd
Conditions Major Depressive Disorder (MDD)
Enrollment 300 participants
Start Date 2025-12-16
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-06